Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Osiris Therapeutics Successfully Defends Key Stem Cell Patent Challenge

Published: Wednesday, February 20, 2013
Last Updated: Wednesday, February 20, 2013
Bookmark and Share
Osiris Therapeutics, Inc. announced the successful conclusion of a patent challenge in Australia by an opponent whose identity under Australian law was not disclosed.

The patent at issue covers the administration of mesenchymal stem cells (MSCs), including Prochymal® (remestemcel-L), for the treatment of inflammatory conditions involving the gastrointestinal tract, including Crohn’s disease and ulcerative colitis.

As acknowledged in the Australian Official Journal of Patents Supplement, all claims to the patent will be maintained in full. The claims specifically include the use of allogeneic MSCs, an attribute central to making an off-the-shelf MSC product possible.

In 2012, Prochymal, an intravenous formulation of MSCs, became the world's first stem cell drug to gain approval by an internationally recognized regulatory authority. Prochymal is also the first drug approved for acute graft versus host disease (GvHD) - a devastating complication of bone marrow transplantation that kills up to 80 percent of children affected, many within just weeks of diagnosis. Prochymal is now approved in Canada and New Zealand, and is currently available in seven other countries including the United States under an Expanded Access Program.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Osiris Therapeutics Provides Update on Groundbreaking Stem Cell Phase II Trial for Type 1 Diabetes
The company is evaluating Prochymal, a formulation of adult mesenchymal stem cells (MSCs), in patients with newly diagnosed type 1 diabetes in this first-of-its kind trial conducted in partnership with JDRF.
Tuesday, January 03, 2012
Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product
Osiris held a successful pre-Biologics License Application meeting for Prochymal used in the treatment of graft-versus-host disease.
Monday, January 19, 2009
Osiris Completes Enrollment in First Worldwide Phase III Stem Cell Trial
The trial will assess safety and efficacy of Prochymal for the treatment of steroid-refractory acute Graft versus Host Disease.
Friday, December 05, 2008
NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
The acquisition includes proprietary adult stem cell bone graft product and processing facility.
Tuesday, May 13, 2008
Osiris Announces Positive Results in Stem Cell Trial to Treat Heart Disease
Osiris reports the results of a double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of the intravenous administration an adult mesenchymal stem cell therapy.
Monday, March 26, 2007
Osiris Recieves FDA Fast Track status and Clearance to Start Phase III trials for Crohn’s Disease Stem Cell Therapy
Company’s Phase III program will be the last phase of testing before it seeks full approval for Crohn’s Disease.
Monday, January 15, 2007
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
JPK NanoWizard® Applied to a Wide Range of Research
The NanoWizard® AFM from JPK is applied for interdisciplinary research at the University of South Australia for applications including smart wound healing and how plants can protect themselves from toxins.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Protein Boosts Rice Yield by 54%
Over-expression of a natural protein in rice plants led to a 54% increase in crop yield and 40% increase in nitrogen-use efficiency.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Soil Nitrogen Age Important for Precision Agriculture
Calculating the age of nitrogen in corn and soybean fields could lead to improved fertilizer application techniques.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!